Additional file 2 of Bridging psychiatry and rare genetic diseases: a scoping review of therapeutic strategies and diagnostic delay paired with healthcare economic burden analysis
(ICER: incremental cost-effectiveness ratios. dominated: strategy costs more but achieves less QALY than the previous strategy or a combination of strategies).
Costs (in 2015 US dollars), incremental cost, quality-adjusted life years (QALYs) gained, incremental QALYs gained, and incremental cost-effectiveness (ICER) of screening and collaborative care for ad
